Prevalence of Scleroderma Spectrum Disorders in the General Population of Estonia

References

• Maricq H R. Detection of scleroderma spectrum disorders by capillary microscopy among patients with Raynaud phenomenon. Microcirculation: An update, M Tsuchiya, M Asano, Y Mishima, M Oda. Excerpta Medica, Amsterdam 1987; 681–4
   Google Scholar
• Maricq H R. Nailfold capillary abnormalities in patients with connective tissue diseases. Microcirculation in Circulatory Disorders, H Manabe, BW Zweifach, K Messmer. Springer-Verlag, Tokyo 1988; 389–94
   Google Scholar
• Asboe-Hansen G. Epidemiology of progressive systemic sclerosis in Denmark. Systemic Sclerosis (Scleroderma), CM Black, AR Myers. Gower, New York 1985; 78
   Google Scholar
• Giordano M, Valentini G, Ara M, Tirri G, Capelli L, Vatti M. Epidemiology of progressive systemic sclerosis in Italy. Systemic Sclerosis (Scleroderma), CM Black, AR Myers. Gower, New York 1985; 72–7
   Google Scholar
• Michet C J, McKenna C H, Elveback L R, Kaslow R A, Kurland L T. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985; 60: 105–13
   PubMed Web of Science ®Google Scholar
• Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988; 27: 286–90
   PubMedGoogle Scholar
• Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991; 283: 366–71
   PubMed Web of Science ®Google Scholar
• Geirsson A J, Steinsson K, Gumundsson S, Sigurøon V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis 1994; 53: 502–5
   PubMed Web of Science ®Google Scholar
• Maricq H R, Weinrich M C, Keil J E, Smith E A, Harper F E, Nussbaum A I. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 998–1006
   PubMed Web of Science ®Google Scholar
• Maricq H R. The microcirculation in scleroderma and allied diseases. Advances in Microcirculation, E Davis. Karger, Basel 1982; 17–52
   Google Scholar
• Priollet P, Vayssairat M, Housset E. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases. Am J Med 1987; 83: 494–8
   PubMed Web of Science ®Google Scholar
• Fitzgerald O, Hess E V, O'Connor G T, Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med 1988; 84: 718–26
   PubMed Web of Science ®Google Scholar
• Kallenberg C GM, Wouda A A, Hoet M H, Van Venrooij W J. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47: 634–41
   PubMed Web of Science ®Google Scholar
• Wollersheim H, Thien T, Hoet M H, Van Venrooy W J. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989; 19: 535–41
   PubMed Web of Science ®Google Scholar
• Weiner E S, Hildebrandt S, Senecal J L, Daniels L, Noell S, Joyal F. Prognostic significance of anticentromere anti-bodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 1991; 34: 68–77
   PubMedGoogle Scholar
• Maricq H R, Harper F E, Khan M M, Tan E M, LeRoy E C. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983; 1: 195–205
   PubMed Web of Science ®Google Scholar
• Liblik V, Kundel H. Pollution sources and formation of air contamination multicomponential concentration fields of organic substances in North-Eastern Estonia. Oil Shale 1996; 13: 43–64
   Web of Science ®Google Scholar
• Valter I, Maricq H R. Prevalence of Raynaud Phenomenon in Tartu and Tartumaa, Southern Estonia. 117–24
   Google Scholar
• Maricq H R, Weinrich M C. Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol 1988; 15: 454–9
   PubMed Web of Science ®Google Scholar
• Maricq H R, Carpentier P H, Weinrich M C, Keil J E, Franco A, Drouet P. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC. USA, vs Tarentaise, Savoie, France. J Rheumatol 1993; 20: 70–6
   PubMed Web of Science ®Google Scholar
• Maricq H R, Carpentier P H, Weinrich M C, Keil J E, Palesch Y, Biro C. Geographic Variation in the Prevalence of Raynaud's Phenomenon: a Five Region Comparison. J Rheumatol 1997; 24: 879–89
   PubMed Web of Science ®Google Scholar
• Maricq H R. Capillaroscopy in Raynaud's syndrome. Vase Med Rev 1992; 3: 3–20
   Google Scholar
• Maricq H R. Nailfold capillary photography. In: Messmer K, Hammersen F, eds. Progress in Applied Microcirculation: Techniques in Clinical Capillary Microscopy. Basel: Karger 1986; 11: 11–27
   Google Scholar
• Masi A T, Rodnan G P, Medsger T A, Jr. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90
   PubMed Web of Science ®Google Scholar
• Morel P A, Chang H J, Wilson J W, Conte C, Falkner D, Tweardy D J. HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies. Hum Immunol 1995; 42: 35–42
   PubMed Web of Science ®Google Scholar
• DeTakats G, Fowler E F. Raynaud's phenomenon. JAMA 1962; 179: 1–8
   PubMedGoogle Scholar
• Velayos E E, Robinson H, Porciuncula F U, Masi A T. Clinical correlation analysis of 137 patients with Raynaud's phenomenon. Am J Med Sci 1971; 262: 347–56
   PubMed Web of Science ®Google Scholar
• Vayssairat M, Fiessinger J N, Housset E. Phénomène de Raynaud: étude prospective de 100 cas. Nouv Presse Med 1979; 8: 2177–80
   PubMedGoogle Scholar
• Takehara K, Soma Y, Ishibashi Y. Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon. Dermatologica 1991; 183: 164–8
   PubMedGoogle Scholar
• Masi A T, D'Angelo W A. Epidemiology of fatal systemic sclerosis (diffuse scleroderma). A 15-Year Survey in Baltimore. Ann Intern Med 1967; 66: 870–83
   PubMed Web of Science ®Google Scholar
• Medsger T A, Jr, Masi A T, Rodnan G P, Benedek T G, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369–76
   PubMed Web of Science ®Google Scholar
• Reveille J D, Durban E, Goldstein R, Moreda R, Arnett F C. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992; 35: 216–8
   PubMedGoogle Scholar
• Vrethem M, Skogh T, Berlin Ernerudh G. J. Autoantibodies versus clinical symptoms in blood donors. J Rheumatol 1992; 19: 1919–21
   PubMed Web of Science ®Google Scholar
• De Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D'Haese D. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993; 11: 393–7
   PubMed Web of Science ®Google Scholar